glp-1 news 2025 november ISPOR 2025: Exploring reasons for discontinuation Eli Lilly to seek approval

doi: 10.1016/j.intimp.2019.105732

2b) and further inhibition of food intake (Fig

A treatment-related increase in benign thyroid C-cell adenomas was seen in males in 0.25 and 0.75 mg/kg/day liraglutide groups with incidences of 12%, 16%, 42%, and 46% and in all female liraglutide-treated groups with incidences of 10%, 27%, 33%, and 56% in 0 (control), 0.075, 0.25, and 0.75 mg/kg/day groups, respectively

Clinical trials stop after a few years, and some of the currently FDA-approved drugs have only been around for a couple of years

Any considerations outside of this age range would need to be specifically determined by a licensed clinician on a case-by-case basis